Invention Application
- Patent Title: ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
-
Application No.: US17642763Application Date: 2020-09-17
-
Publication No.: US20220348651A1Publication Date: 2022-11-03
- Inventor: Michael DiDonato , Mirek Dostalek , Christoph Erkel , Javier Estrada Diez , Anna Galkin , Scott Martin Glaser , Klaus Felix Hartlepp , Yong Jia , Deborah A. Knee , Alexandra Kraus , Christian Cho-Hua Lee , Luigi Manenti , Sarah Michelle Rue , Jian Shi , Xenia Karola Wezler , Gabrielle Wong
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- International Application: PCT/IB2020/058648 WO 20200917
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; C07K16/30
Abstract:
Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
Information query
